- Home
- PBYI vs ARQQ Comparison
PBYI vs ARQQ Comparison
Compare PBYI & ARQQ Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- PBYI
- ARQQ
- Stock Information
- Founded
- PBYI 2010
- ARQQ 2017
- Country
- PBYI United States
- ARQQ United Kingdom
- Employees
- PBYI N/A
- ARQQ N/A
- Industry
- PBYI Biotechnology: Pharmaceutical Preparations
- ARQQ Computer Software: Prepackaged Software
- Sector
- PBYI Health Care
- ARQQ Technology
- Exchange
- PBYI Nasdaq
- ARQQ Nasdaq
- Market Cap
- PBYI 138.4M
- ARQQ 194.9M
- IPO Year
- PBYI N/A
- ARQQ N/A
- Fundamental
- Price
- PBYI $3.07
- ARQQ $16.50
- Analyst Decision
- PBYI Strong Buy
- ARQQ Strong Buy
- Analyst Count
- PBYI 1
- ARQQ 1
- Target Price
- PBYI $7.00
- ARQQ $52.00
- AVG Volume (30 Days)
- PBYI 275.3K
- ARQQ 292.3K
- Earning Date
- PBYI 05-08-2025
- ARQQ 05-19-2025
- Dividend Yield
- PBYI N/A
- ARQQ N/A
- EPS Growth
- PBYI 37.78
- ARQQ N/A
- EPS
- PBYI 0.62
- ARQQ N/A
- Revenue
- PBYI $230,468,000.00
- ARQQ $293,000.00
- Revenue This Year
- PBYI N/A
- ARQQ $1,818.77
- Revenue Next Year
- PBYI N/A
- ARQQ N/A
- P/E Ratio
- PBYI $4.92
- ARQQ N/A
- Revenue Growth
- PBYI N/A
- ARQQ N/A
- 52 Week Low
- PBYI $2.23
- ARQQ $3.72
- 52 Week High
- PBYI $5.20
- ARQQ $52.79
- Technical
- Relative Strength Index (RSI)
- PBYI 51.76
- ARQQ 55.25
- Support Level
- PBYI $2.88
- ARQQ $15.00
- Resistance Level
- PBYI $3.14
- ARQQ $18.24
- Average True Range (ATR)
- PBYI 0.14
- ARQQ 1.09
- MACD
- PBYI 0.01
- ARQQ 0.19
- Stochastic Oscillator
- PBYI 64.00
- ARQQ 66.08
About PBYI Puma Biotechnology Inc
Puma Biotechnology Inc is a biopharmaceutical company that develops and commercializes innovative products to enhance cancer care and improve treatment outcomes for patients. It is currently commercializing NERLYNX, an oral version of neratinib, for the treatment of HER2-positive breast cancer. Also it develops alisertib. Alisertib is a selective, small-molecule inhibitor of aurora kinase A that is designed to disrupt mitosis leading to apoptosis of rapidly proliferating tumor cells that are dependent on aurora kinase A.
About ARQQ Arqit Quantum Inc.
Arqit Quantum Inc is a cybersecurity company that has pioneered a symmetric key agreement technology that makes the communications links of any networked device or data at rest secure against current and future forms of cyber attack - even an attack from a quantum computer. The company delivers its symmetric key agreement technology via its product QuantumCloud. The firm operates in one segment that is, the provision of cybersecurity services via satellite and terrestrial platforms. The company operates and generates its revenue from UK.